Drs Corey J. Langer, MD and Joshua Bauml discuss the key take-home points from the 21st Annual Perspectives in Thoracic Oncology meeting held November 18-19, 2016 in New York.
Drs Morton Coleman and John P. Leonard summarize the key take-home points presented on lymphoma during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications.
Drs Morton Coleman and Richard R. Furman summarize the key take-home points presented on CLL during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications.
Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications.
This Expert Perspectives discussion features a panel of experts summarizing the key take-home points from their presentations during the JAK Inhibitors in Myeloproliferative Neoplasms symposium.
Drs Joseph R Mikhael and Ruben A Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic myelogenous leukemia and myeloproliferative neoplasms.
Recent advances in understanding the biology of MPN have spurred significant discoveries that have the potential to change the paradigm of how MPN and MDS are diagnosed and treated.
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the availability of CDK 4/6 inhibitors in women with estrogen receptor-positive (ER+) metastatic breast cancer.
This Expert Perspectives activity features the clinical faculty from a symposium held at the 2016 Annual Meeting of the Oncology Nursing Society sharing highlights from the symposium and additional relevant clinical commentary.
This online enduring activity provides a summary of the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages from the 2016 European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes.